CASTLEMAN＇S disease（CD）,a rare lymphoproliferative disorder of unknown etiology, was first described in 1956 as a benign mass in the mediastinum. Although CD can present anywhere in the body, 70% of the cases are ...CASTLEMAN＇S disease（CD）,a rare lymphoproliferative disorder of unknown etiology, was first described in 1956 as a benign mass in the mediastinum. Although CD can present anywhere in the body, 70% of the cases are in the chest along the tracheobronchial tree or hilum of the lung in the middle mediastinum; however, they can also occur in the anterior or posterior compartments. CD is classi-fied as unicentric （UCD） or multicentric （MCD） based on the anatomical distribution, and histologically as hya-line-vascular, plasma cell, or mixed subtypes.1 Although MCD is less common than UCD, it can be rapidly pro-gressive and often fatal.展开更多
Background: The heart and great vessels were once thought to be relatively resistant to the damaging effect of radiation therapy. There is now clear evidence that thoracic irradiation may cause acute inflammation and ...Background: The heart and great vessels were once thought to be relatively resistant to the damaging effect of radiation therapy. There is now clear evidence that thoracic irradiation may cause acute inflammation and progressive fibrosis of different structures, including the heart valves, the myocardium and the pericardium, the coronary arteries and the conduction system. As new therapies have improved survival, many patients with cancer (mostly Hodgkin’s disease and breast cancer) are now at risk of cardiovascular (CV) complications following radiation therapy. Objectives: To raise awareness of CV complications following chest irradiation. Method: We present 5 patients that we treated during a short period of time (between June 2013 (6/2013) and February 2015 (2/2016)), who suffered CV involvement that needed therapy, following chest irradiation. Conclusions: Patients after chest irradiation should be followed periodically, in order to diagnose and treat CV complications, in time.展开更多
文摘CASTLEMAN＇S disease（CD）,a rare lymphoproliferative disorder of unknown etiology, was first described in 1956 as a benign mass in the mediastinum. Although CD can present anywhere in the body, 70% of the cases are in the chest along the tracheobronchial tree or hilum of the lung in the middle mediastinum; however, they can also occur in the anterior or posterior compartments. CD is classi-fied as unicentric （UCD） or multicentric （MCD） based on the anatomical distribution, and histologically as hya-line-vascular, plasma cell, or mixed subtypes.1 Although MCD is less common than UCD, it can be rapidly pro-gressive and often fatal.
文摘Background: The heart and great vessels were once thought to be relatively resistant to the damaging effect of radiation therapy. There is now clear evidence that thoracic irradiation may cause acute inflammation and progressive fibrosis of different structures, including the heart valves, the myocardium and the pericardium, the coronary arteries and the conduction system. As new therapies have improved survival, many patients with cancer (mostly Hodgkin’s disease and breast cancer) are now at risk of cardiovascular (CV) complications following radiation therapy. Objectives: To raise awareness of CV complications following chest irradiation. Method: We present 5 patients that we treated during a short period of time (between June 2013 (6/2013) and February 2015 (2/2016)), who suffered CV involvement that needed therapy, following chest irradiation. Conclusions: Patients after chest irradiation should be followed periodically, in order to diagnose and treat CV complications, in time.
